NASDAQ · RNAZ
Healthcare · Biotechnology
$1.78
Down-$0.02 (-1.12%)
Updated Oct 7, 2026, 8:10 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · RNAZ
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
RNAZ closed at $1.78 after 21 trading sessions, down 5.82% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.77 | $1.8154 | $1.71 | $1.78 | 47.34K |
| Oct 5, 2026 | $1.65 | $1.87 | $1.57 | $1.76 | 65.73K |
| Oct 2, 2026 | $1.58 | $1.66 | $1.545 | $1.57 | 15.5K |
| Oct 1, 2026 | $1.6733 | $1.74 | $1.52 | $1.545 | 16.71K |
| Sep 30, 2026 | $1.7482 | $1.7482 | $1.64 | $1.68 | 6.73K |
| Sep 29, 2026 | $1.73 | $1.81 | $1.60 | $1.63 | 11.01K |
| Sep 28, 2026 | $1.71 | $1.79 | $1.63 | $1.71 | 40.68K |
| Sep 25, 2026 | $1.60 | $1.70 | $1.60 | $1.69 | 14.76K |
| Sep 24, 2026 | $1.62 | $1.74 | $1.62 | $1.65 | 28.66K |
| Sep 23, 2026 | $1.835 | $2.39 | $1.6214 | $1.68 | 425.72K |
| Sep 22, 2026 | $1.87 | $1.9109 | $1.7066 | $1.77 | 59.51K |
| Sep 21, 2026 | $1.67 | $1.9699 | $1.67 | $1.76 | 66.2K |
| Sep 18, 2026 | $2.00 | $2.00 | $1.65 | $1.65 | 30.9K |
| Sep 17, 2026 | $1.70 | $1.72 | $1.63 | $1.72 | 58.15K |
| Sep 16, 2026 | $1.66 | $1.71 | $1.5785 | $1.68 | 18.7K |
| Sep 15, 2026 | $1.65 | $1.6999 | $1.60 | $1.60 | 18.52K |
| Sep 14, 2026 | $1.65 | $1.72 | $1.65 | $1.65 | 20.66K |
| Sep 11, 2026 | $1.68 | $1.74 | $1.6265 | $1.69 | 11.45K |
| Sep 10, 2026 | $1.72 | $1.83 | $1.69 | $1.69 | 26.09K |
| Sep 9, 2026 | $1.86 | $1.95 | $1.75 | $1.78 | 30.94K |
| Sep 8, 2026 | $1.98 | $2.03 | $1.88 | $1.89 | 37.79K |
The latest Smart Investors Daily articles mentioning RNAZ.
Company
Market Activity
Research & News
RNAZ research
Company profile and research snapshot.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 6, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 18, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 3, 2026
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/
Benzinga · Feb 5, 2026
Benzinga · Feb 5, 2026
As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and have
Benzinga · Feb 5, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RNAZ.
